A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, ...
How well our brain functions depends heavily on the performance of our nerve cells. That is why they are regularly checked for their proper function -- defective cell components are marked, disposed ...
Parkinson's disease is the second most common neurodegenerative disease, affecting over 10 million people worldwide. Some forms of Parkinson's disease are characterized by an inability of cells to ...
The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...
June 26 -- WEDNESDAY, June 25 (HealthDay News) -- People taking dopamine agonists to treat Parkinson's disease are at risk for impulse-control disorders such as compulsive gambling, buying and sexual ...
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson’s disease and improved motor skills, the company reported on Thursday. Tavapadon ...
A novel biodegradable gel delivers Parkinson’s medications via a single weekly shot, potentially replacing current regimens of multiple pills per day. The corresponding study was published in Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results